Vaccinex, Inc.: Series B $25M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Inflammation, X - Oncology

Vaccinex (Rochester, NY) a research and development stage antibody platform company focused on oncology and inflammation closed a $25M Series B financing. Participants include Teva Pharmaceuticals, Pan Atlantic Bank & Trust, Biocon and Toronto Investment Group.

Apr

2008

Affomix, Corp.: Series A $7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Microarray

Affomic (New Haven, CT) a development stage biotechnology company designing antibody microarrays closed a $7M Series A financing. Participants include Connecticut Innovations, Elm Street Ventures, and Four Seasons Ventures.

Apr

2008

Affimed Therapeutics, AG: Series B $7.8M

Posted in I - Series B, Q - 1Q08, R - INTERNATIONAL, X - Antibody

Affimed (Germany) developer of recombinant antibody therapeutics had a second closing of an additional $7.8M Series B financing from Novo Nordisk bringing the total round to $47.2M. Earlier participants include BioMedInvest, OrbiMed Advisors, Life Sciences Partners and FirstVentury.

Feb

2008

Alder Biopharmaceuticals, Inc.: Series C $40M

Posted in I - Series C, Q - 1Q08, R - NORTH WEST, X - Antibody

Alder Biopharma (Bothell, WA) developer of unique antibody technologies that may increase antibody potency, accelerate production cycles, and lower production costs closed a $40M Series C financing. Participants include Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.

to top of page...